Interactive Decision Support Tool: Expert Guidance on Selecting Treatment for HER2-Positive Metastatic Breast Cancer
  • CME

LAUNCH TOOL
ACCEPT DISCLAIMER AND LAUNCH TOOL
Use this Interactive Decision Support Tool to compare your choice of therapy for patients with HER2-positive metastatic breast cancer with those of 5 breast cancer experts.
Neelima Denduluri, MD, FASCO
Ian E. Krop, MD, PhD
Heather McArthur, MD, MPH
Sara Tolaney, MD, MPH
person default
Tiffany A. Traina, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Released: August 20, 2020 Expiration: August 19, 2021

Disclaimer

Disclaimer: Access to and use of this Interactive Decision Support Tool titled, “Expert Guidance on Selecting Therapy for HER2-Positive Metastatic Breast Cancer,” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate clinicians on making optimal management choices for treating individuals with HER2-positive metastatic breast cancer. The information provided is based on current guideline recommendations and the expert guidance of Neelima Denduluri, MD, FASCO; Ian E. Krop, MD, PhD; Heather McArthur, MD, MPH; Sara Tolaney, MD, MPH; and Tiffany A. Traina, MD.

Note: The current tool was developed in July/August 2020 and reflects the expert recommendations at that time.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the Expert Guidance on Selecting Therapy for HER2-Positive Metastatic Breast Cancer has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2020 Clinical Care Options, LLC. All rights reserved.

Interactive Decision Support Tool
HER2+ MBC Treatment Tool
LAUNCH TOOL
ACCEPT DISCLAIMER AND LAUNCH TOOL

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply the latest clinical evidence when making management decisions for patients with HER2-positive metastatic breast cancer, including treatment of CNS metastases
  • Plan effective therapy for patients with HER2-positive metastatic breast cancer and CNS metastases
  • Understand potential patient concerns and educational needs for patients on new or novel agents for HER2-positive metastatic breast cancer

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Neelima Denduluri, MD, FASCO

Clinical Assistant Professor
Georgetown University
Washington, DC
Medical Oncologist
Virginia Cancer Specialists
Co-Director, Virginia Cancer Specialists Research Program
Associate Chair, US Oncology Breast Cancer Research Committee
Arlington, Virginia

Neelima Denduluri, MD, FASCO, has disclosed that she has received funds for research support paid to her institution from Amgen, AstraZeneca, Daiichi, Genentech, and Novartis.
Ian E. Krop, MD, PhD

Associate Professor of Medicine
Harvard Medical School
Associate Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Ian E. Krop, MD, PhD, has disclosed that he has received funds for research support paid to his institution from Daiichi Sankyo, Genentech/Roche, and Pfizer and consulting fees from Bristol-Myers Squibb, Context Therapeutics, Daiichi Sankyo, Genentech/Roche, MacroGenics, Merck, Novartis, and Taiho Oncology and that his spouse receives salary from and has ownership interest in Amag.
Heather McArthur, MD, MPH

Associate Professor
Department of Medicine
Medical Director, Breast Oncology
Samuel Oschin Comprehensive Cancer Center
Cedars-Sinai Medical Center
Los Angeles, California

Heather McArthur, MD, MPH, has disclosed that she has received funds for research support from Bristol-Myers Squibb and Merck and consulting fees from AstraZeneca, Bristol-Myers Squibb, Daiichi-Sankyo, Genentech, Genomic Health, Immunomedics, Merck, Pfizer, and Puma.
Sara Tolaney, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Associate Director
Susan F. Smith Center for Women's Cancer
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Senior Physician

Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Sara Tolaney, MD, MPH, has disclosed that she has received funds for research support from AbbVie, Athenex, AstraZeneca, Bristol-Myers Squibb, Celldex, Cyclacel, Daiichi-Sankyo, Eisai, Exelixis, G1 Therapeutics, Genentech, Immunomedics, Lilly, Merck, NanoString, Nektar, Novartis, Odonata, Paxman, Pfizer, Puma, Sanofi, Seattle Genetics, and Silverback Therapeutics.
Tiffany A. Traina, MD

Associate Attending Physician
Clinical Director, Breast Medicine Service
Section Head, Triple Negative Breast Cancer Research Program
Breast Medicine Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Assistant Professor of Medicine, WCMC
New York, New York

Tiffany A. Traina, MD, has disclosed that she has received consulting fees from Aduro Biotech, Advaxis, AstraZeneca, Athenex, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Genentech/Roche, Genomic Health, Halozyme, Innocrin Pharma, Ionis, Merck, Pfizer, Puma, and Samsung; fees for non-CME/CE services from Genentech/Roche; and funds for research support paid to her institution from Astellas, AstraZeneca, Carrick, Daiichi Sankyo, Eisai, Genentech/Roche, Immunomedics, Innocrin, Novartis, and Pfizer.

Staff

Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This improvement activity will be available for medical oncologists, advanced practice providers, pharmacists, and other members of the clinical oncology team.

Goal

The goal of the educational program is to accelerate evidence adoption and to prepare clinicians to engage with their patients in making personalized care decisions about the use of the latest treatment regimens in metastatic breast cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 20, 2020, through August 19, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

On-demand Webcast featuring expert discussion of new therapies for relapsed/refractory HER2-positive metastatic breast cancer, from a live CCO Webinar

Adam M. Brufsky, MD, PhD
Program Director
Thomas Bachelot, MD, PhD person default Cristina Saura, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: September 11, 2020 Expired: September 10, 2021

Expert commentary from Cristina Saura, MD, PhD, with answers to frequently asked questions on managing HER2-positive metastatic breast cancer from CCO

person default Cristina Saura, MD, PhD Released: September 11, 2020

Commentary from Adam Brufsky, MD, on managing interstitial lung disease during trastuzumab deruxtecan treatment for HER2-positive metastatic breast cancer

Adam M. Brufsky, MD, PhD Released: September 10, 2020

From Clinical Care Options (CCO), watch video of expert discussions of testing for and targeting of HER2, HER3, and TROP2 in metastatic breast cancer

Mark D. Pegram, MD Michael F. Press, MD, PhD Physicians: maximum of 1.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s) ABPath MOC: maximum of 1.25 Lifelong Learning (Part II) and Self-Assessment Module (SAM) point(s) Released: September 10, 2020 Expired: September 9, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Supported by an educational grant from
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?